Whalesbook
Bhai, ye GLP-1 drugs ne toh obesity aur diabetes treatment mein jaise revolution la diya hai. Socho, 2025 tak lagbhag 12.4% American adults inka use kar rahe hain weight loss ke liye, jo 2024 ki shuruaat se double ho gaya hai! Estimates toh yahi keh rahi hain ki 2035 tak ye market $190 billion tak pahunch jayegi, aur sirf obesity wale segment se hi $66.57 billion kamaaye jayenge. Itni tezi se koi drug pehle kabhi adopt nahi hui.
Is race mein sabse aage hain Eli Lilly aur Novo Nordisk. Eli Lilly ne toh Mounjaro aur Zepbound se Q1 2026 mein hi $13.4 billion kama liye, aur Mounjaro akela $8.7 billion de gaya. 2025 mein inka total sale $36.5 billion raha! Eli Lilly ki market value lagbhag $931 billion hai, aur P/E ratio 35-43 ke aas-paas hai. Dusri taraf, Novo Nordisk ka GLP-1 revenue 2025 mein 56% badhkar $21.9 billion ho gaya. Wegovy ne $7.1 billion kamaye. Novo Nordisk ki market value $152-$200 billion hai, aur P/E ratio 11-13 ke aas-paas hai. Matlab Lilly ka valuation kafi high hai.
Ab sabse interesting baat ye hai ki GLP-1 drugs ne pharma R&D ko bhi poori tarah se badal diya hai. Pichhle 16 saalon mein pehli baar obesity drugs R&D pipeline mein cancer drugs se bhi badi player ban gayi hain, lagbhag 25% forecast sales ke saath. Iski wajah se industry ka R&D return 7% tak pahunch gaya hai. Lekin agar GLP-1 drugs ko hata dein toh ye productivity gir kar sirf 2.9% ho jati hai! Is concentration se 'bubble' ka khatra badh raha hai. Aur haan, ek drug banane ka average kharcha bhi badhkar $2.67 billion ho gaya hai 2025 tak.
Market mein takkar kaafi zabardast hai. Eli Lilly ka tirzepatide, Mounjaro/Zepbound, kuch comparisons mein Novo Nordisk ke semaglutide (Ozempic/Wegovy) se zyada effective dikha hai. Dono companies ne oral versions bhi launch kar diye hain, jisse rivalry aur badh gayi hai. Ab pricing pressure bhi ek bada issue ban raha hai. Eli Lilly ko 2026 mein pricing reforms ka bada asar dikhega. Novo Nordisk toh US mein apne GLP-1 drugs ki list price 35%-50% tak kam kar raha hai taaki zyada logon tak pahunch sake aur market share bacha sake.
Achhi khabar ye hai ki GLP-1 drugs ki jo shortages chal rahi thi, woh ab 2025 tak semaglutide aur 2024 ke end tak tirzepatide ke liye kam ho gayi hain. Regulatory attention bhi badh gaya hai compounded GLP-1 products par, jisse branded drugs banane walon ko fayda ho sakta hai.
Basically, pharma sector ka GLP-1 drugs par itna zyada depend karna ek bada concentration risk hai. Agar is segment mein koi gadbad hui toh poore industry ke R&D returns aur market valuations par bura asar padega. Development costs zyada, competition tez aur pricing pressure – ye sab milkar financial risk badha rahe hain. Agar innovation slow hui ya regulatory challenges aaye toh industry ki growth ruk sakti hai. Eli Lilly ka high P/E ratio (35-43) versus Novo Nordisk ka (11-13) dikhata hai ki investors Lilly se zyada growth expect kar rahe hain, jiska matlab hai ki agar expectations poori nahi hui toh girne ka risk bhi zyada hai.
Analysts mostly optimistic hain, lekin sabki rai thodi alag hai. Barclays ne toh Eli Lilly ka price target $1400 kar diya hai. Novo Nordisk ke liye ratings mixed hain, mostly 'Hold' rating hai. Eli Lilly ne 2026 ke liye apna revenue forecast $82-$85 billion tak badha diya hai, jo 25% increase hai. Global GLP-1 market mein growth toh abhi bhi tezi se hone wali hai, metabolic diseases ke liye ye ek bada commercial opportunity hai.